The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALPMY Detailed Price Forecast - CNN Money||View ALPMY Detailed Summary - Google Finance|
|View ALPMY Detailed Summary - Yahoo! Finance||View ALPMY Stock Research & Analysis - Zacks.com|
|View ALPMY Trends & Analysis - Trade-Ideas||View ALPMY Major Holders - Barrons|
|View ALPMY Call Transcripts - NASDAQ||View ALPMY Breaking News & Analysis - Seeking Alpha|
|View ALPMY Annual Report - CompanySpotlight.com||View ALPMY OTC Short Report - OTCShortReport.com|
|View ALPMY Fundamentals - TradeKing||View ALPMY SEC Filings - Bar Chart|
|View Historical Prices for ALPMY - The WSJ||View Performance/Total Return for ALPMY - Morningstar|
|View the Analyst Estimates for ALPMY - MarketWatch||View the Earnings History for ALPMY - CNBC|
|View the ALPMY Earnings - StockMarketWatch||View ALPMY Buy or Sell Recommendations - MacroAxis|
|View the ALPMY Bullish Patterns - American Bulls||View ALPMY Short Pain Metrics - ShortPainBot.com|
|View ALPMY Stock Mentions - StockTwits||View ALPMY Stock Mentions - PennyStockTweets|
|View ALPMY Stock Mentions - Twitter||View ALPMY Investment Forum News - Investor Hub|
|View ALPMY Stock Mentions - Yahoo! Message Board||View ALPMY Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALPMY - SECform4.com||View Insider Transactions for ALPMY - Insider Cow|
|View ALPMY Major Holdings Summary - CNBC||View Insider Disclosure for ALPMY - OTC Markets|
|View Insider Transactions for ALPMY - Yahoo! Finance||View Institutional Holdings for ALPMY - NASDAQ|
|View ALPMY Stock Insight & Charts - FinViz.com||View ALPMY Investment Charts - StockCharts.com|
|View ALPMY Stock Overview & Charts - BarChart||View ALPMY User Generated Charts - Trading View|
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
Posted on Sunday June 03, 2018
-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- TOKYO and BOTHELL, Wash. , June 3, 2018 /PRNewswire/ -- ...
Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World
Posted on Thursday May 31, 2018
TOKYO, May 31, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the launch of the third annual Astellas Oncology C3 Prize (Changing Cancer Care), a global challenge aimed at inspiring non-treatment ideas that may improve cancer care for patients and their loved ones.
How Is Merck’s Hospital Acute Care Segment Positioned?
Posted on Wednesday May 30, 2018
Merck & Company’s (MRK) Bridion generated revenue of $204 million in Q1 2018 compared to $148 million in Q1 2017, which reflected a ~38% rise YoY (year-over-year) and a 2% fall sequentially.
U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Posted on Tuesday May 29, 2018
TOKYO , May 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has ...